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Summary 
Objective. To investigate the consequences of IGF proteins dysfunction in development of 
endometrial adenocarcinomas.  
Methods. The expression of IGF 2 and IGF 1R was correlated with the expression of IGF 2R 
and apoptosis rate in 59 human endometrial adenocarcinomas, 10 endometrial hyperplasias 
and 7 normal tissues. The presence of mutations in the IGF 2R gene was followed in 46 
adenocarcinomas. We also examined the effect of IGF 1 receptor blockage on cancer cell 
proliferation. In groups of either IGF 2 positive or IGF 2 negative tumors (stages III and IV) 
the expression of IGF 1, IGF 1R was correlated with cell proliferation index and telomerase 
activity.  
Results. The expression of IGF 2 and IGF 1R was much higher in malignant tissue of stages 
III and IV than in tumors of stages I and II and normal or hyperplastic endometrium. This 
correlated with a decreased apoptosis rate and IGF 2R expression. Eight adenocarcinomas 
expressed biallelic mutation of the IGF 2R gene. The specific inhibition of IGF 1R and IGF 2 
decreased tumor cell proliferation in IGF 2/IGF 1R-positive tumors. Also, the positive 
correlation between increased expression of IGF 1 and IGF 1R proteins and increased 
telomerase activity and cell proliferation index was found in both, IGF2 negative and IGF 2 
positive tumors.  
Conclusion. Our data suggest that IGF 1, IGF 2 and their receptors, are involved in the 
progression of endometrial adenocarcinomas. As cancer cell proliferation can be abrogated by 
blocking mRNA or protein products of these genes, tumors with extensive involvement of the 
IGF 2 pathway would be candidates for the therapeutics strategies aimed at interference with 
this pathway. 
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Introduction 
 Under normal circumstances, proteins of the IGF family (IGF 1 and IGF 2, their 
receptors and binding proteins) regulate cell proliferation, metabolism and maintain 
differentiated cell function. In addition, in endometrium, the IGF protein system is thought to 
function as a mediator of steroid hormone actions through autocrine/paracrine mechanisms. 
Namely, endometrial stroma cells produce IGF 1 and IGF 2 as well as high affinity IGF-
binding proteins (IGF BPs), the most abundant being IGF BP-1, whereas epithelial cells and, 
to a lesser extend, stromal cells contain cell membrane receptors for IGF's. On the other hand, 
estrogen stimulates IGF 1/IGF 1R gene expression, associated with endometrial carcinoma 
development [1]. 
 The IGF 1 and IGF 2 signaling pathway involve two specific receptors. IGF 1R (which 
is virtually ubiquitous) mediates IGF 1 and IGF 2 action on prenatal growth and IGF 1 action 
on postnatal growth. On the other hand, as far as IGF ligands are concerned, IGF 2R/M6-P is 
involved in the clearance of IGF 2 from the circulation. Furthermore, at least six IGF-binding 
proteins (IGF BP 1-6) also regulate the function of both, IGF 1 and IGF 2. It is obvious from 
the above mentioned, that the inappropriate expression of any IGF peptide could be involved 
in abnormal cell function. It is known that not only IGF 2, but also IGF 1R, are commonly 
overexpressed in many tumors. As their appropriate level and/or interaction regulate cell 
growth, it is obvious that overexpression of either of them (or both) may be involved in 
enhanced tumor growth [2]. The proposed mechanism of autocrine IGF 2 action on malignant 
proliferation came from its elevated secretion by tumors and tumor derived cell lines [3, 4].  
 On the other hand, the physiological significance of IGF 1R activation by either IGF 1 
or IGF 2 was brought into focus by gene targeting experiments in mice [5]. Mice with 
homozygous targeted mutations of the IGF 1 receptor were severely growth retarded and died 
immediately after birth, indicating these receptors are important for cell proliferation and 
 4
survival. Later it was also shown that signaling through these tyrosine kinase growth factor 
receptors is one of the key regulators of cell motility and adhesion. However, functional IGF 
1R is also required for cell transformation, which appears to involve autocrine stimulation 
through overexpressed IGF 1R, at least in tumors of epithelial origin [6]. Moreover, it has 
been shown that a blockade of the IGF 1R function reverses the transformed phenotype of 
tumors derived from both experimental animals and humans [7, 8]. 
 Contrary to the already mentioned IGF 2/IGF 1R oncogenic action, IGF 2R/M6-P 
protects the cells from neoplastic impulses, at least those caused by IGF 2. Namely, the 
binding of IGF 2 to IGF 2R/M6-P results in the degradation of ligand, making it unable to 
activate IGF 1R. However, IGF 2R/M6-P has been shown to be mutated in a number of 
human tumors, identifying it as a tumor suppressor. 
 In developed countries, adenocarcinoma of the endometrium is the most common 
gynecological cancer. Histopathologically, it is characterized by the proliferation of abnormal 
glands in an abnormal relationship to one another. Evidence has been accumulated that links 
IGF family peptides with the development of this tumor type. However, their exact role in 
endometrial adenocarcinoma development is still unclear. 
 The aim of this study was to investigate the role of IGF 2 and its receptors (IGF 1R 
and IGF 2R/M6-P) in endometrial adenocarcinoma. We measured expression of IGF 2 and its 
receptors mRNA in order to analyze the possible correlation among these genes activity and 
cell proliferation, as well as the tumor stage. As disruption of the IGF 2/IGF 1R pathway can 
be accomplished through the binding of growth factors, blockage of receptors or inhibition of 
secondary targets, we also examined the effect of IGF 1 receptor blockage by αIR3 
monoclonal antibodies or antisense oligodeoxynucleotides on cell proliferation. An additional 
purpose of our investigation was to determine if IGF 2R/M6-P is a target for mutation. Our 
data suggest that increased expression of IGF 1, IGF 2 and IGF 1R may be an important 
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contributor to the risk of endometrial cancer. Together with concomitant down regulation of 
IGF 2R they are involved in the progression of endometrial adenocarcinoma. In addition, 
oncogenic expression of IGF 1, IGF 2 and IGF 2R strongly correlated with the late stage 
disease compared to with early stage. Therefore evaluation of these IGF’s expression may 
have clinical implication in endometrial cancer prognosis and treatment. Our results also 
indicate that IGF 2/IGF 1R antagonists can reduce the growth of human endometrial cancer 
and could be used as an alternative adjuvant therapy for management of endometrial cancer.  
 
Materials and Methods 
Tumor tissues 
 Ten endometrial hyperplasias and 91 human primary endometrial adenocarcinomas 
(34 of stages I and II, and 57 of stages III and IV) were obtained from the Croatian Human 
Tumor Bank. These were obtained from patients treated surgically (females, aged 45 to 78, 
mean 62 year). Endometrial hyperplasias (obtained from post-menopausal women) were 
proliferative lesions that showed minimal glandular complexity and crowding and had no 
cytological atypia. The epithelial lining was one cell layer thick, and the stroma between the 
glands was abundant. Endometrial carcinomas were pure or endometrial adenocarcinomas, 
composed entirely of glandular cells. All tumors were tested immunohistochemically – 
Alcian-PAS, CEA, variety of keratins. The histopathology was confirmed by a pathologist. 
Immediately after surgical removal, the one part of tissue was snap frozen in liquid nitrogen 
and stored at -800C, and another was brought to the laboratory for subsequent cultivation of 
tumor cells. Sections of frozen samples (10 hyperplasia, 34 adenocarcinomas of stages I and 
II and 25 adenocarcinomas of stages III and IV) adjacent to those used for histopathology 
were used for RNA extraction. Forty six samples were used for mutational analysis. For each 
tumor sample, normal tissue, not immediately adjacent to cancerous tissue, was used as a 
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control for LOH/mutation analysis. Part of each tumor sample was also embedded in paraffin 
for immunohistochemical analysis of IGF protein expression. Sections of each paraffin block 
were stained with hematoxylin and eosin to confirm the exact tissue analyzed (Table 1).  
 Seven normal post-menopausal endometrial tissue specimens were used as a control 
for mRNA analysis. 
 For the proliferation assay, [3H]-thymidine labeling, apoptosis and telomerase assay, 
fresh resected samples were collected into sterile vessels containing RPMI 1640 medium with 
10% heat-inactivated fetal calf serum and brought to the laboratory for subsequent cultivation 
of tumor cells.  
 All persons gave their informed consent prior to inclusion in the study. The local 
ethics committee approved the study. 
Immunohistochemistry 
 This was performed on formalin-fixed, paraffin-embedded tissue using the avidin-
biotin-peroxidase method. Sections, cut at 4 µm, were subjected to a heat-induced epitope 
retrieval technique in 10 mM citrate buffer (pH 6.0) in an 850 W microwave oven for 10 
minutes. Anti-IGF1 (goat; 50 µg/ml; R&D Systems), anti-IGF 2 (mouse, Upstate 
Biotechnologies, Lake Placid, N.Y) and anti-Ki-67 (mouse, 10 µg/ml; DAKO Cytometrics, 
Denmark) monoclonal antibodies were diluted 1:50, and incubated for 15 to 18 hours. Anti 
IGF 1R (Santa Cruz Biotechnologies, Santa Cruz, CA) was diluted 1:100 and incubated for 
15-18 hours. Detection was achieved using the DAKO LSAB 2 kit (Carpinteria, CA). Anti 
IGF 2R/M6P rabbit polyclonal antibody was a generous gift from Zeneco, USA 
(http://www.geneimprint.com). Detection was achieved using the DAKO LSAB 2 kit, in 
accordance with the manufacturer’s instructions. Negative controls were stained by 
substitution of the primary antibodies with non-immune mouse or rabbit immunoglobulins. 
Appropriate positive controls (thyroid gland tissue for IGF 1R, Wilms’ tumor for IGF 2 and 
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normal colon for IGF 2R/M6P) were stained positively. The tumor cells showed strong 
diffuse cytoplasmic immunopositivity for IGF 2 and IGF 2R/M6P, and cytoplasmic and focal 
membranous reactivity for IGF 1R. The intensity of staining was arbitrarily judged as: 
negative (0), weak (1), moderate (2) and strong (3). 
RNA extraction and RNase protection assay 
 Total RNA extraction was performed as described previously [9]. Tissue mRNA for 
IGF 2 and IGF 1R was analyzed by an RNase protection assay. A sample of total RNA (20 
µg) was hybridized in a buffer containing 80% formamide, molar excess of [32P]UTP-labeled 
antisense RNA probe (1x106 dpm; 603 and 411 bases long for IGF 2 and IGF 1R, 
respectively), a control human β-actin probe (247 bp), and tRNA as a negative control [10]. 
The hybridization was carried out at 450C for 16 hours. After hybridization, the RNA samples 
were digested with RNases A and T1. Protected hybrids were extracted with 
phenol/chloroform, ethanol precipitated, and electrophoresed on 8% polyacrylamide/8 M urea 
denaturing gel. The autoradiograms were scanned by densitometer (Pharmacia, LKB, 
Uppsala, Sweden) [10]. 
Loss of Heterozygosity Analysis and Mutation Detection in IGF 2R/M6P 
 We utilized two polymorphisms, dinucleotide (GT) repeat sequence and a 
tetranucleotide insertion/deletion (ACAA) site, present in the 3’-untranslated region of the 
human IGF 2R/M6P gene, to determine the frequency of LOH [11]. The reaction conditions 
for PCR, primer sequences and a detailed method description have been published previously 
[12]. 
In tumors with LOH at one IGF 2R/M6P locus, the remaining allele was screened for 
mutations in the ligand binding regions by direct sequencing of PCR products [13]. The 
regions screened for mutations were exons 8-11, exons 27-29, exon 31, exons 33 and 34 and 
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exons 37-39. The exon specific forward and reverse PCR primers that were used have been 
published [14]. 
Cultivation of tumor cells 
 Tumor tissue, without necroses, was cut into small pieces and pressed through a nylon 
sieve. Cells (approximately 4 x 105) were put into T75 flasks covered with an extracellular 
matrix with an RPMI medium supplemented with 10% fetal bovine serum, 5% human serum, 
1% glutamine, and 20 mM HEPES. Tumor cell cultures were maintained as monolayers [15]. 
Cell proliferation and apoptosis after blocking of IGF 2/IGF 1R by monoclonal 
antibodies or antisense oligodeoxynucleotides.  
 Tumor cell proliferation was evaluated by [3H]-thymidine incorporation assay. Cancer 
cells, seeded in 96-well plates (2x103 cells/well) were grown in DMEM medium for four days 
with or without the addition of 1000 ng/ml of αIR3 monoclonal antibodies (AMS 
Biotechnology, Lugano, Switzerland) or with or without the addition of sense and antisense 
oligodeoxynucleotides applied to 3x104 cells/well. Eighteen hours before the end of 
incubation [3H]-thymidine (spec. activity 25 mCi/ml) was added to a final concentration of 1 
µCi/ml. The cells were harvested on glass wool filters and the incorporated radioactivity was 
measured in a scintillation counter. Tumor cell proliferation was expressed in cpm/minute 
[10]. All oligodeoxynucleotides were synthesized as mixed phosphorothiodates. The IGF 1R: 
antisense 5’TCCTCCGGAGCCAGACTT3’ (complementary to codons 21-29 of the signal 
sequence of the human IGF 1R) and sense 5’AAGTCTGGCTCGGAGGA 3’; IGF 2: 
antisense 5’ TTCCCCATTGGGATTCCCAT 3’ (corresponding to the IGF 2 mRNA initiation 
site) and sense 5’ ATGGGAATCCCAATGGGGAA 3’. 
 For the apoptosis analysis, 2x105 cells/well were treated in the same way as described 
for the [3H]-thymidine proliferation assay. 
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Analysis of Apoptosis 
 A FACScan apoptosis analysis was performed as described previously [16]. Two 
million cells per sample were fixed with 2% paraformaldehyde in PBS, washed twice with 
TBS (50 mM Tris HCl in saline solution), and permeabilized for 1 min with ice cold acetone. 
Staining was performed by incubating cells for 1 hr at 370C in 25 µL of TUNEL reaction 
mixture – in situ Cell Death Detection Kit (Boehringer, Mannheim, Germany). Samples were 
analyzed by FACScan (Becton Dickinson, Erembodegem-Aalst, Belgium). 
Telomerase assay 
 The telomerase assay was performed with a commercial telomerase PCR ELISA kit 
(Roche Molecular Biochemicals, Indianapolis, IN) in accordance with Bosserhoff et al [17] 
and the manufacturer’s protocol. Absorbance at 450 nm was measured using an ELISA plate 
reader (Labsystems, Multiscan MS) [18]. Cells were lysed and protein concentrations were 
determined by Bradford assay. Two µg of protein were used for each telomerase PCR 
reaction. Telomerase assay was also performed using positive and negative controls as 
specified in the kit. 
Statistical analysis 
 Data are shown as mean ± standard deviation. A Student's t-test was performed to 
compare the results between different groups of samples. The normality of the data was tested 
by Kolmogorov test. The assumption of equal group variances was tested with Levene’s test. 
In the case of violated assumptions for the analysis, the maximum likelihood analysis 
suggested the optimal transformation data. 
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Results 
Expression of IGF 2 and IGF 1R mRNA and Apoptosis 
 The expression of the IGF 2 and IGF 1R gene mRNA was much higher in malignant 
than in normal or hyperplastic endometrial tissue (p<0.001). Moreover, it was significantly 
higher in stages III and IV versus cancers of stages I and II (p<0.001, Fig. 1). 
 The immunohistochemical analysis of IGF 2, IGF 1R, as well as IGF 2R/M6-P protein 
expression, was carried out on 34 endometrial adenocarcinomas of stages I and II, 25 
adenocarcinomas of stages III and IV, as well as 10 hyperplasias. The expression of IGF 
2/IGF 1R proteins was negligible (negative or of weak intensity, 32 out of 34 samples for IGF 
2 and 31 out of 34 samples for IGF 1R) in tumors of stages I and II (not shown). However, it 
was much higher, of moderate or strong positivity, in tumors of more advanced stages (III and 
IV; p<0.0001; Chi-square = 27.28, df = 6 for IGF 2 and p<0.0001, Chi-square = 37.11; df = 6 
for IGF 1R) (Table 2) compared to both normal tissue (4 samples negative and 3 of weak 
positivity for IGF 2/IGF 1R proteins), as well as to the tumors of stages I and II. The IGF 2 
protein was overexpressed in 60% of tumors, of which 86% overexpressed IGF 1R. There 
was also a strong correlation between extend of IGF 2 protein expression and number of 
apoptotic cells. When compared to the data for these two parameters in hyperplasia samples 
statistical significance was at the level of p<0.001. The opposite, although to a lesser extend, 
was observed for the IGF 2R/M6-P protein expression. Most of the tumors of stages I and II 
(28 out of 34 samples, 82 %) were of strong or moderate IGF 2R/M6-P positivity (not 
shown). Among tumors of stages III and IV, 10 were either negative or of weak intensity for 
IGF 2R/M6-P protein (p<0.001, Chi-square = 29.32; df = 6 compared to both tumors of stages 
I and II and hyperplasia. All these tumors also expressed a decreased number of apoptotic 
cells (p<0.001). The remaining samples expressed the IGF 2R/M6-P protein with moderate or 
strong intensity. However, it is interesting to note that almost all the samples with negligible 
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IGF 2R/M6-P expression overexpressed at the same time IGF 2 and/or IGF 1R, and vice 
versa. These findings point to the fact that, in endometrial adenocarcinomas, IGF 2 and IGF 
1R act as oncogenes, while IGF 2R/M6-P acts as a tumor suppressor gene.  
The opposite results were observed in hyperplasias. Most of the IGF 2/IGF 1R weak 
positive hyperplasias were strongly or moderately positive for IGF 2R/M6-P having also a 
higher number of apoptotic cells. 
Mutation of IGF 2R/M6-P Gene 
 Two polymorphisms in the 3’-untranslated region of the IGF 2R/M6-P gene were used 
to screen 46 endometrial adenocarcinomas for LOH. Of 46 normal tissue specimens, seventy 
percent (32 samples) were informative (heterozygous) for at least one polymorphic site. Of 
the corresponding 32 endometrial adenocarcinomas, 16 had LOH at the IGF 2R/M6-P locus. 
The remaining allele, in 8 out of 16 LOH patients, contained mutation in the mannose 6-
phosphate IGF 2 binding domain (Table 3). The following exons were affected: 27, 28, 33 
and 34.  
Tumor Cell Proliferation After Blocking of IGF 2/IGF 1R Pathway 
Eight different endometrial adenocarcinomas, 5 in stage 2 and 3 in stage 3, were 
grown in culture and used to determine the correlation between IGF 1R mRNA expression 
and the extend of cell proliferation (3H-thymidine incorporation). Thymidine uptake 
correlated well with the higher level of IGF 1R mRNA (Table 4). 
 The effect of the IGF 1 receptor blocking antibody on cell proliferation is shown in 
Table 5. In IGF 2 positive cells, cell proliferation was strongly diminished. On the contrary, 
there was no statistically different effect of αIR3 treatment on IGF 2 negative cell culture. 
 To ascertain the role of IGF 2 and IGF 1R as a potential mediator in growth 
promotion, 2 endometrial adenocarcinomas positive for IGF 2 mRNA and one negative, 
grown in vitro, were treated with sense and antisense oligodeoxynucleotides to IGF 1R or IGF 
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2 mRNA (Table 5). Antisense oligodeoxynucleotides to IGF 2 in concentration of 20 µM 
significantly reduced the growth of both cell lines for 95% and 85%, respectively. At a 
concentration of 10 µM, antisense oligodeoxynucleotides to IGF 1R also inhibited the growth 
of both tested cell lines by 46% and as much as 86%. Contrary to this, sense 
oligodeoxynucleotides to IGF 2 or IGF 1R had no effect on tumor cell proliferation. There 
was no effect of either antisense or sense deoxyoligonucleotides on either IGF 2 or IGF 1R in 
IGF 2 negative cells. 
The relationship among IGF 1/IGF 2/IGF 1R protein and telomerase activity and 
proliferation index 
 The positive correlation between the increased expression of protein for both IGF 1 
and IGF 1R and increased telomerase activity (p<0.0267 for IGF1 and p<0.3707 for IGF 1R) 
and the cell proliferation index (p<0.3707 for IGF 1 and p=05. for IGF 1R) was found in all 
eleven IGF 2 positive endometrial adenocarcinomas of stages III and IV. Similar results were 
also observed in a group of 21 IGF 2 negative tumors of stages III and IV (IGF 1/telomerase 
p<0.0062; IGF 1R/telomerase p<0.0515; IGF 1/Ki-67 p<0.0001; IGF 1R/Ki-67 p<0.0013) 
(Table 6). 
 
Discussion 
 IGF 1 and 2 secreted by tumor cells play a major role in tumor progression mostly 
through the binding and activation of IGF 1R. Such an interplay has been shown in a variety 
of human tumors. Here we provide the evidence on the role of IGF system in endometrial 
malignancy and provide novel insights into the complex mechanisms that contribute to its 
oncogenic potential. 
 In our study, the majority of endometrial adenocarcinomas overexpressed IGF 1/IGF 2 
and/or IGF 1R. At the same time, these tumors, especially those of advanced stages, failed to 
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express IGF 2R. Together with the fact that almost all such samples had a decreased apoptosis 
rate, the increased proliferation index, as well as increased telomerase activity, indicate the 
important role of proteins of the IGF family in the pathogenesis of endometrial 
adenocarcinoma. Similar finding were also shown for colon [3], lung [8], gastric [10] and 
gynecological cancers [19], as well as hemangiopericytomas [20]. Furthermore, all these data 
point to the autocrine action between IGF 1 and /or IGF 2 and their receptors, supported by 
the fact that abrogation of the IGF 2/IGF 1R function inhibited cancer cell proliferation in 
vitro.  
Data concerning the level of IGF 1 in plasma or in endometrial adenocarcinoma cells 
are different. Although there are some reports indicating its decreased or unchanged presence 
[21], we and some others have shown the opposite. Contrary to these, are the findings 
concerning IGF 1R, which have been shown continuously to be overexpressed in endometrial 
adenocarcinoma [22, 23]. Knowing that the action of IGF 1 is mediated by IGF 1R, it is 
obvious that some other proteins might interfere with IGF 1 action, contributing to the 
different findings concerning the IGF 1 level in cancer cells. In this respect, it has been shown 
that in endometrial adenocarcinoma epithelial cells, IGF 1 binding to IGF 1R is also 
modulated (usually inhibited) by the presence of IGF-binding proteins (mostly IGF BP3) 
which are secreted into the circulation by IGF 1 target cells [23, 24, 25]. However, the 
function of cell-surface-associated insulin-like growth factor binding proteins in IGF 1 
stimulation is controversial. Bermont et al. [26] showed that in HEC-1A endometrial 
adenocarcinoma cells responsive to IGF 1, the IGF BP3 is the main binding protein 
expressed, and both soluble and cell-associated forms act as inhibitors of IGF 1-induced 
cellular proliferation. In addition to IGF BPs, insulin, as well as nutritional energy balance 
and physiological activity levels, appears to be an important determinant of IGF 1 bioactivity 
[27].  
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 When expressed normally, IGF 2 is an indispensable mitogenic peptide for a number 
of cell types. However, there are now a number of disease situations in which the level of IGF 
2 is elevated, leading to increased cell proliferation and inhibition of apoptosis, as seen in 
many human and animal tumors. In endometrial adenocarcinoma, the IGF 2 protein/mRNA 
level is also increased [21, 25] Although the exact meaning of these findings and the role of 
IGF 2 in the etiology of endometrial cancer is still unclear, the accumulated evidence points to 
its autocrine stimulation through IGF 1R, which is an absolute requirement for at least the 
maintenance of the transformed phenotype. In support to this possibility, there are also the 
results presented in this paper. The concomitant elevated expression of IGF 2 (sometimes 
associated with elevated IGF 1) and IGF 1R resulted in an increased proliferation rate and 
telomerase activity, and a decreased apoptosis rate of cancer cells, all characteristics of 
neoplastic growth. Additionally, when the IGF 2 and/or receptor function was blocked by 
using monoclonal antibodies or antisense oligonucleotides, the cell growth in vitro was 
efficiently abrogated, showing for the first time that these two kinds of targeted therapies can 
be successfully applied to the treatment of endometrial adenocarcinoma. As far as we know 
there are only limited data on targeted therapy of endometrial adenocarcinoma. So it was 
shown that the growth of endometrial adenocarcinoma cells can also be inhibited by the use of 
the LH-RH antagonist SB-75 (Ac-D-Nal(2)1,D-Phe(4Cl)2,D-Pal(3)3,D-Cit6,D-Ala10)-GnRH 
[28]. This interferes with the autocrine activity of IGF 2 and also directly inhibits the growth-
stimulatory effects of IGFs, probably through effects on a post-receptor mechanism. Of a 
special clinical interest might also be the finding that overexpressed IGF 1R signaling might 
provoke resistance to trastuzumab (Herceptin) an anti HER2/neu receptor monoclonal 
antibody [29], main drug for treatment breast cancer overexpressing HER2/neu receptors. 
However, amplification of HER2/neu has also been reported for endometrial cancer, and 
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trastuzumab is currently under Phase II clinical trial for stage III and IV, and recurrent 
endometrial adenocarcinoma.  
 All together, ours, as well as other experiments have unequivocally shown that a 
decrease in the level of IGF 2 and number of IGF IR causes a reversal of the transformed 
phenotype [7, 8, 10, 12, 30].  
 The mechanism by which the IGF 2 gene is overexpressed in endometrial 
adenocarcinomas presented in this paper was not explored. However, it is known that IGF 2 
overexpression can be accomplished by multiple mechanisms such as loss of imprinting 
(LOI), loss of heterozygosity (LOH) with paternal duplication, and alteration in IGF-binding 
proteins [31]. Which of the mechanisms underlay IGF 2 overexpression in endometrial 
adenocarcinoma is still in question, although biallelic expression was shown to occur in some 
(3 out of 12 tested) endometrial tumor samples [32]. However, as LOI did not correlate with 
IGF 2 mRNA overexpression, the authors of these results suggested «that biallelic expression 
of IGF 2 may be subject to down regulation, despite loss of imprinting».  
Consistent with the IGF's autocrine regulation of endometrial adenocarcinoma growth 
are also the findings of mutations in IGF 2R gene reported previously to be present in 15% of 
examines samples [33]. Expressed at the cell surface, IGF 2R is constitutively endocytosed, 
where its main role is binding and internalization and subsequent degradation of non-
glycosylated IGF 2. As shown in this paper, the mutated IGF 2R gene caused decrease in the 
level of corresponding protein, which was a more common event in advanced stages of 
endometrial adenocarcinoma. As these changes were associated with the concomitant 
overexpression of IGF 2/IGF 1R, it is very likely that the IGF 2R gene acts as a tumor 
suppressor in endometrial adenocarcinoma, similar to what has been shown for some other 
human tumors. Namely, biallelic mutations, usually point mutation or small deletion in one 
allele and loss of heterozygosity in the other, have been reported in a variety of human 
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malignancies, including hepatocarcinoma and adrenocortical tumors [34, 35], aggressive early 
breast cancer [36], and lung cancers [12, 13]. Furthermore, the IGF2/M6P locus at 6q has 
been reported to be a hot spot for mutation in tumors, including malignant melanoma [37], 
ovarian cancer [38] non-Hodgkin lymphoma [39], and renal cell carcinoma [40]. Down 
regulation of the IGF 2R/M6P promotes the growth of transformed cells by sustaining IGF 2, 
which binds to and activates IGF 1R and the insulin receptor to increase intracellular growth 
signals [41]. However, it has also been shown that IGF 2R/M6P is a receptor for granzyme B 
during immune system mediated apoptosis [42]. Therefore, tumor cell lines deficient in 
functional IGF 2R/M6P would also have an inherent resistance to the immune system, which 
could contribute to the easier tumor development. In support of this belief, there is also the 
observation that IGF 2R/M6P is secreted by breast cancer lines and primary metastatic breast 
cancer cells [43]. If it is supposed that granzyme could also bind to this soluble form of IGF 
2R/M6P (at least its larger form), then again, cytotoxic T-cell induced apoptosis mediated by 
granzyme would be inhibited, allowing, when such conditions exist, overexpressed IGF 2 to 
bind without restriction to IGF 1R, promoting increased cell proliferation. Contrary to such 
deliberation, stand the results showing that the soluble form of IGF 2R/M6P retains its ability 
to bind IGF 2 and blocks IGF 2-stimulated DNA synthesis in isolated rat hepatocytes, thus 
blocking tumor growth mediated by IGF 2 [44]. 
In support of the autocrine loop between IGF 2 and IGF 2R, are the data obtained with 
mutant mice lacking IGF 2R/M6P. These usually die perinatally, but are completely rescued 
from lethality in the absence of IGF 2. IGF2R/M6-P deficient mice have also elevated levels 
of the circulating IGF binding protein (IGF BP-3) and show a strong IGF BP-6 
immunoreactivity in all pancreatic islet cells and in secretory granules of different size in 
acinar cells and interlobular connective tissue of exocrine pancreas. Fibroblasts derived from 
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double mutant mice missort the lysosomal protease cathepsin D, and are able to degrade 
endocytosed IGF BP-3 intracellularly, though with lower efficiency [45]. 
In addition to IGF's, but in close relation to them, estrogens are also strong growth 
stimulators of endometrial tumors. Paradoxically, tamoxifen, a known antiestrogen, also 
stimulates their growth. The mode of action of estrogen can be partially explained by the 
modulation of the insulin-like growth factor autocrine or paracrine action. On the other hand, 
tamoxifen does not affect the number or affinity of IGF 1R [46]; rather, similar to estradiol, it 
increases IGF 1-stimulated tyrosine phosphorylation of cellular substrates. In contrast, in 
MCF-7 mammary cancer cells, tamoxifen reduced IGF 1-induced tyrosine phosphorylation in 
the presence of estradiol. Tamoxifen caused a 3-fold decrease in IGF BPs. Moreover, a 
reduction in soluble IGF BPs was also observed, making the IGF peptides more available to 
the receptors [46]. 
 In conclusion, our results support the hypothesis that the production of IGF 1, IGF 2, 
IGF 1R, and IGF 2R, different from that in normal tissue, influence endometrial 
adenocarcinoma growth by autocrine mechanism. Tumor cells overexpress IGF 1R which 
efficiently binds, also overexpressed, IGF 2, since IGF 2 “clearance”-IGF 2R are at the same 
time underexpressed and/or nonfunctional. These lead to increased telomerase activity, and 
the inversion of the balanced proliferation/apoptosis rate usual for normal cells. The already 
described loop can be abrogated by targeted therapy.  
 
Acknowledgement 
This work was supported by the Grant # 0098092 from the Ministry of Science Education and 
Sport, Republic of Croatia. 
 
 
 
 
 
 18
References 
 
[1] McCampbel AS, Broaddus RR, Loose DS, Davies PJA. Oveexpression of the insulin-like 
growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. 
Clin Cancer Res 2006; 12: 6373 – 78. 
 
[2] Samani AA, Yakar S, Leroith D, Brodt P. The role of IGF system in cancer growth and 
metastasis: overview and recent insights. Endocr Rev 2006. doi: 10.1210/er2006-0001 
 
[3] Freier S, Weiss O, Eran M, Flyvbjerg A, Dahan R, Nephesh I, Safra T, Shiloni E, Raz I. 
Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the 
colon. Gut 1999; 44 : 704-8. 
 
[4] Pavelić K, Buković D, Pavelić J. The role of insulin-like growth factor 2 and its receptors 
in human tumors. Mol Med 2002; 8 : 771-80. 
 
[5] Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of 
the genes encoding insulin-like growth factor I (igf-I) and type 1 IGF receptor (Igf 1r). Cell 
1993; 75 : 59-72. 
 
[6] LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 
2003; 195 : 127-37. 
 
[7] Adachi Y, Lee CT, Carbone DP. Genetic blockade of the insulin-like growth factor 1 
receptor for human malignancy. Novartis Found Symp 2004; 262 : 177-89. 
 
[8] Pavelić J, Pavelić Lj, Karadža J, Križanac Š, Unešić J, Spaventi Š, Pavelić K. Insulin-like 
growth factor family and combined antisense approach in therapy of lung carcinoma. Mol 
Med 2002; 8 : 149-57. 
 
[9] Gall-Trošelj K, Kušić B, Pećina-Šlaus N, Pavelić K, Pavelić J. Nested polymerase chain 
reaction for detection of hepatitis C virus RNA in blood derivatives. Eur J Clin Chem Clin 
Biochem 1995; 33 : 733-36. 
 
 19
[10] Pavelić K, Kolak T, Kapitanović S, Radošević S, Spaventi Š, Krušlin B. Gastric cancer: 
the role of insulin-like growth factor 2 (IGF 2) and its receptors (IGF 1R and M6-P/IGF 2R). J 
Pathol 2003; 201 : 430-8. 
 
[11] Hol FA, Geurds MP, Hamel BC, Mariman EC. Improving the polymorphism content of 
the 3’UTR of the human IGF 2R gene. Hum Mol Gen 1992; 1 : 347-50. 
 
[12] Pavelić J, Križanac Š, Kapitanović S, Pavelić Lj, Samaržija M, Pavičić F, Spaventi Š, 
Jakopović M, Herceg-Ivanovi Z, Pavelić K. The consequences of insulin-like growth 
factors/receptors dysfunction in lung cancer. Am J Resp Cell Mol Biol 2005; 32 : 65-71. 
 
[13] Kong F-M, Anscher MS, Washington MK, Killian JK, Jirtle RL. M6P/IGF2R is mutated 
in squamous cell carcinoma of the lung. Oncogene 2000; 19 : 1572-8. 
 
[14] Killian JK, Jirtle RL. Genomic structure of the human M6P/IGF 2 receptor. Mamm 
Genome 1999; 10 : 74-7. 
 
[15] Pavelić K, Bulbul MA, Slocum HK, Pavelic ZP, Rustum YM, Niedbala MJ, Bernacki 
RJ. Growth of human urological tumors on extracellular matrix as as model for the in vitro 
cultivation of primary human tumor explants. Cancer Res 1986; 46 : 3653-62.  
 
[16] Sard L, Accornero P, Tonielli S, Delia D, Bunone G, Campiglio M, Colombo MP, 
Gramegna M, Croce CM, Pierotti MA, Sozzi G. The tumor-suppressor gene FHIT is involved 
in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96 : 
8489-92. 
 
[17] Bosserhoff AK, Glabl A, Stolz W, Buettner R. Detection of telomerase activity in skin, 
melanocytic nevi, and melanoma by telomerase PCR ELISA. Biochimica 1997; 3: 16-18. 
 
[18] Watterau LM, Francis MJ, Ma L, Cohen P. Insulin-like growth factor I stimulates 
telomerase activity in prostate cancer. J Clin Endocrinol Metab 2003; 88: 3354-3359. 
 
 20
[19] Mathur SP, Landen CP, Datta SM, Hoffman MC, Mathur RS, Young RC. Insulin-like 
growth factor II in gynaecological cancers: a preliminary study. Am J Reprod Immunol 2003; 
49: 113-119. 
 
[20] Pavelić K, Spaventi Š, Glunčić V et al. The expression and role of insulin-like growth 
factor II in malignant hemangiopericytomas. J Mol Med 1999; 77: 865-869. 
 
[21] Oh JC, Wu W, Tortolero-Luna G et al. Increased plasma levels of insulin-like growth 
factor 2 and insulin-like growth factor binding protein 3 are associated with endometrial 
cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 748-752. 
 
[22] Peiro G, Lohse P, Mayr D, Diebold J. Insulin-like growth factor-I receptor and PTEN 
protein expression in endometrial carcinoma. Correlation with bax and bcl-2 expression, 
microsatellite instability status, and outcome. Am J Clin Pathol 2003; 120: 78-85. 
 
[3] Hirano S, Ito N, Takahashi S, Tamaya T. Clinical implications of insulin-like growth 
factors through the presence of their binding proteins and receptors expressed in 
gynaecological cancers. Eur J Gynaecol Oncol 2004; 25: 187-191.  
 
[24] Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R. Serum levels of insulin-like 
growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk. Br J 
Cancer 2003; 89: 1697-1704.  
 
[25] Petridou E, Koukoulomatis P, Alexe DM, Voulgaris Z, Spanos E, Trichopoulos D. 
Endometrial cancer and the IGF system: a case-control study in Greece. Oncology 2003; 64: 
341-345. 
 
[26] Bermont L, Fauconnet S, Lamielle F, Adessi GL. Cell-associated insulin-like growth 
factor-binding proteins inhibit insulin-like growth factor-I-induced endometrial cancer cell 
proliferation. Cell Mol Biol 2000; 46: 1173-1182. 
 
[27] Kaaks R. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of 
epidemiological evidence. Novartis Found Symp 2004; 262: 247-260. 
 
 21
[28] Kleinman D, Roberts CT Jr, LeRoith D, Schally AV, Levy J. Sharoni Y. Regulation of 
endometrial cancer cell growth by insulin-like growth factor and the luteinizing hormone-
releasing hormone antagonist SB-75. Regul Pept 1993; 48:91-98. 
 
[29] Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-1 receptor 
signaling and resistance to Trastuzumab (Herceptin). J Natl Cancer Int 2001; 93: 1852-57. 
 
[30] Bahr C, Groner B. The insulin-like growth factor-1 receptor (IGF-1R) as a drug target: 
novel approaches to cancer therapy. Growth Horm Res 2004; 14 : 287-95. 
 
[31] Toretsky JA, Helman LJ. Involvement of IGF-II in human cancer. J Endocrinol 1996; 
149: 367-372. 
 
[32] Roy RN, Gerulath AH, Cecutti A, Bhavnani BR. Loss of IGF-II imprinting in 
endometrial tumors: overexpression in carcinosarcoma. Cancer Lett 2000; 153: 67-73. 
 
[33] Ouyang H, Shiwaku HO, Hagiwara H, Miura K, Abe T, Kato Y, Ohtani H, Shiiba K, 
Souza RF, Meltzer SJ, Horri A. The insulin-like growth factor II receptor gene is mutated in 
genetically unstable cancers of the endometrium, stomach, and colorectum. Cancer Res 1997; 
57: 1851-4. 
 
[34] Kishimoto Y, Morisawa T, Kitano M et al. Loss of heterozygosity of the mannose 6-
phosphate/insulin-like growth factor II receptor and p53 genes in human hepatocellular 
carcinoma. Hepatol Res 2001; 20: 68-83. 
 
[35] Leboulleux S, Gaston V, Boulle N, Le Bouc Y, Gicquel C. Loss of heterozygosity at the 
mannose 6-phosphate/insulin-like growth factor 2 receptor locus: a frequent but late event in 
adrenocortical tumorigenesis. Eur J Endocrinol 2001; 144: 163-168. 
 
[36] Chappell SA, Walsh T, Walker RA, Shaw JA. Loss of heterozygosity at the mannose 6-
phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in 
early breast carcinomas.Br J Cancer 1997; 76: 1558-1561. 
 
 22
[37] Millikin D, Meese E, Vogelstein B, Witkowski C, Trent J. Loss of heterozygosity for loci 
on the long arm of chromosome 6 in human malignant melanoma.Cancer Res 1991; 51: 5449-
5453. 
 
[38] Foulkes W. Tumour suppressor genes in ovarian cancer. BMJ 1993; 307:1009. 
 
[39] Gaidano G, Hauptschein RS, Parsa NZ et al. Deletions involving two distinct regions of 
6q in B-cell non-Hodgkin lymphoma. Blood 1992; 80: 1781-1787. 
 
[40] Morita R, Saito S, Ishikawa J et al. Common regions of deletion on chromosomes 5q, 6q, 
and 10q in renal cell carcinoma. Cancer Res 1991; 51: 5817-5820. 
 
[41] Osipo C, Dorman S, Frankfater A. Loss of insulin-like growth factor II receptor 
expression promotes growth in cancer by increasing intracellular signaling from both IGF-I 
and insulin receptors. Exp Cell Res 2001; 264: 388-396. 
 
[42] Motyka B, Korbutt G, Pinkoski MJ et al. Mannose 6-phosphate/insulin-like growth 
factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced 
apoptosis. Cell 2000; 103: 491-500. 
 
[43] Confort C, Rochefort H, Vignon F. Insulin-like growth factors (IGFs) stimulate the 
release of alpha 1-antichymotrypsin and soluble IGF-II/mannose 6-phosphate receptor from 
MCF7 breast cancer cells. Endocrinology 1995; 136: 3759-3766. 
 
[44] Scott CD, Weiss J. Soluble insulin-like growth factor II/mannose 6-phosphate receptor 
inhibits DNA synthesis in insulin-like growth factor II sensitive cells. J Cell Physiol 2000; 
182: 62-68.  
 
[45] Braulke T, Dittmer F, Gotz W, von Figura K. Alteration in pancreatic immunoreactivity 
of insulin-like growth factor (IGF)-binding protein (IGFBP)-6 and in intracellular degradation 
of IGFBP-3 in fibroblasts of IGF-II receptor/IGF-II-deficient mice. Horm Metab Res 1999; 
31: 235-241. 
 
 23
[46] Kleinman D, Karas M, Danilenko M, Arbell A, Roberts CT, LeRoit D, Levy J, Sharoni 
Y. Stimulation of endometrial cancer cell growth by tamoxifen associated with increased 
insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF 
binding proteins. Endocrinology 1996; 137: 1089. 
 24
Tables 
 
 
Table 1. Number of specimens and type of analysis 
____________________________________________________________________   
        Number of tissue specimens 
                                              _____________________________________________                                 
Analysis            Normal            Hyperplasia     Endometrial adenocarcinoma 
                 stages I, II      stages III, IV 
RNase assay 
     IGF 2/IGF 1R       7a       10b    34c         25d 
 
Immunohistochem. 
     IGF 1    7a       10b           32e 
     IGF 2    7a       10b     34c    25d + 32e 
     IGF 1R    7a         10b    34c    25d + 32e 
     IGF 2R    7a         10b    34c             25d 
      
 Ki-67                           32e 
               
Apoptosis           10b        34c            25d 
 
Telomerase                32e 
 
[3H]-thymidine           5c          3d 
incorporation 
 
Mutations          21 (12 inf)c        25 (20 inf)d 
 
Blocking assay           1c                  2d  
a, b, c, d, e – the same specimens  
Inf – informative samples  
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Table 2. IGF 2, IGF 1R, IGF 2R/M6P protein expression and apoptosis in endometrial 
adenocarcinoma and hyperplasia 
 
Samples IGF 2 IGF 1R IGF 2R/M6P Apoptosis 
ADENOCARCINOMA* 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
 
HYPERPLASIA 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
 
 
3 
3 
3 
3 
3 
3 
3 
3 
2 
3 
3 
3 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
0 
0 
0 
 
 
0 
0 
0 
1 
1 
1 
1 
2 
2 
2 
 
3 
3 
3 
2 
3 
3 
3 
3 
3 
3 
2 
2 
2 
1 
1 
2 
1 
2 
2 
2 
1 
2 
2 
2 
1 
 
 
0 
0 
1 
1 
2 
2 
2 
1 
2 
3 
 
0 
0 
0 
0 
1 
1 
1 
1 
1 
2 
2 
3 
2 
3 
2 
3 
3 
1 
3 
2 
2 
3 
3 
2 
3 
 
 
2 
2 
2 
2 
2 
3 
3 
3 
3 
1 
 
13 
12 
19 
19 
26 
18 
10 
15 
30 
49 
17 
31 
25 
51 
29 
66 
58 
44 
37 
41 
40 
32 
63 
60 
70 
 
 
44 
38 
70 
47 
39 
69 
59 
50 
55 
46 
* stages III and IV 
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Table 3. Mutations in IGF 2R/M6P gene in endometrial adenocarcinoma 
Tumor  
 stage         LOH (allele 1)  Mutation    (allele 2) 
    1  yes   GGT to CGT in exon 27 
    1  yes   GGG to CGG in exon 33 
    2  yes   G insert in poly-G repeat region in exon 28 
    2  yes   GCC to ACC in exon 34 
    3  yes   GGG to AGG in exon 34 
    3  yes   GGG to CGG in exon 33 
    3  yes    GGG to AGG in exon 34       
    4  yes   G insert in poly-G repeat region in exon 28 
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Table 4. IGF 1R mRNA expression and [3H]-thymidine incorporation in endometrial 
adenocarcinomas 
 
Tumor stage 
 
 IGF 1R mRNA* 
 
[3H]-thymidine incorporation** 
2 310 
210 
130 
50 
40 
7649±1207 
3950±879 
3144±1126 
1260±331 
860±311 
3*** 440 
290 
130 
9384±2155 
4251±977 
1592±213 
  
*The values of IGF 1R mRNA represent the relative density of the bands expressed as 
an percentage of decrease or increase compared to the expression in normal tissue 
(100%) 
 
**
 cpm calculated as mean + standard deviation of three parallel samples in two 
independent experiments; fourth passage of the cells used for experiments; even after 
fifth passage the cells retained their initial phenotype 
 
*** moderately differentiated formed by glandular elements; nuclei were vesicular, 
pleomorphic. Mitotic figures are abundant and abnormal. Cells are moderatly or poorly 
differentiated growing in solid sheets. Positive for c-myc, p53 and erb B-2. 
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Table 5. Effect of IGF 1 receptor blocking antibody and antisense 
deoxyoligonucleotides to IGF 2 or IGF 1R on cell proliferation of IGF 2 positive 
and negative adenocarcinoma cells† 
 
Tumor stage Treatment IGF 2 
positive/negative 
tumors 
Cell 
proliferation†† 
cpm              %††† 
P 
2* DMEM 
αIR3 
+ 4124 
1158            72↓ 
 
P<0.001 
3** DMEM 
αIR3 
+ 5624 
  429            92↓ 
 
P<0.001 
3*** DMEM 
αIR3 
- 2520 
1914            24↓ 
 
NS 
2* sense IGF 2 (20 µM) 
antisense (20 µM) 
+ 3115            25↓ 
  224            95↓ 
NS 
P<0.001 
3** sense IGF 2 (20 µM) 
antisense (20 µM) 
+ 4904            13↓ 
  819            85↓ 
NS 
P<0.001 
2* sense IGF 1R (10 µM) 
antisense (10 µM) 
+ 7200            74↑ 
2247            46↓ 
P<0.001 
P<0.001 
3** sense IGF 1R (10 µM) 
antisense (10 µM) 
+ 6824            21↑ 
  818            86↓ 
NS 
P<0.001 
3*** sense IGF 2 (20 µM) 
antisense (20 µM) 
- 3405            35↑ 
4041            60↑ 
NS 
NS 
3*** sense IGF 1R (10 µM) 
antisense (10 µM) 
- 3307            31↑ 
3979            58↑ 
NS 
NS 
 
- 
†the same type of experiments was conducted on all together 8 tumor cell lines, 4 
positive and 4 negative for IGF 2. As the results were the same among cell lines of a 
certain group, and to contribute to the simplicity of the table, only the results for 3 cell 
lines (2 positive and one negative for IGF 2) were presented. IGF 2 positive (negative) 
tumors retained their ability to express (or not) IGF 2 in culture.  
- 
†
 
†measured by [3H]-thymidine incorporation (cpm); mean of three parallel samples 
- 
†††
 % of inhibition ↓ /stimulation ↑ 
- *, **, *** - the same tumor cell lines 
- NS – not significant 
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Table 6. Expression of IGF 1 and IGF 1R protein and telomerase activity in IGF 2 positive 
and negative tumors of stages III and IV. 
 
Patient  IGF 1  IGF 1R Telomerase*  Ki-67  
                                          
                                               IGF 2 positive tumors 
 
1  3  3   250  3 
2  3  2   220  3 
3  3  3   200  3 
4  3  3   170  2 
5  3  3   410  1 
6  3  3   280  3 
7  3  3   400  3 
8  2  1   190  1 
9  0  2   170  3 
10  0  3   110  1 
11  0  2   110  2 
 
IGF 2 negative tumors 
1  3  3   370  2 
2  3  2   240  2 
3  3  3   130  2 
4  3  3   120  3 
5  3  2   380  3 
6  3  2   120  3 
7  3  2   200  2 
8  3  2   150  2 
9  3  2   430  3 
10  3  3   370  3 
11  1  2   120  2 
12  1  2   100  1 
13  2  0   190  2 
14  1  0   120  2 
15  1  3   170  2 
16  1  0   140  0 
17  2  3   200  3 
18  2  3   210  2 
19  0  1   130  1 
20  0  0   100  0 
21  0  0   100  1 
* the values represent the relative telomerase activity expressed as a percentage of increase 
when compared to referral values (100%) 
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Figure legend 
 
Figure 1. Expression of insulin-like growth factor 2 mRNA (A) and insulin-like growth factor 
receptor type 1 (IGF 1R) mRNA in endometrial hyperplasia (10 specimens) and endometrial 
adenocarcinoma (stages I and II, 34 specimens; stages III and IV, 25 specimens) compared 
with normal adjacent tissue (7 specimens). The values represent the relative density of the 
bands expressed as a percentage of decrease or increase when compared to referral values 
(100%) in normal tissue. There was a significant difference (p<0.001) between normal and 
cancer tissues and hyperplasia and cancer as well as between endometrial adenocarcinoma of 
stage I and II versus stages III and IV (  Non-Outlier Max, Non-Outlier Min; ٱ 75%, 25%; ▫ 
median). 
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